Vicki joins DxS from Invitrogen, where she was a Key Account Manager. She has also previously worked for Bayer Diagnostics, Tecan and Dade Baring in a variety of roles including account management, technical support and training.
Dr. Stephen Little, CEO of DxS Ltd., said: “Vicki brings considerable experience in the diagnostics field, having worked for some of the sectors’ leading companies. Her appointment at DxS comes at a crucial time as companion diagnostics become increasingly important, and her experience will prove invaluable in helping DxS to increase its tumour mutation product portfolio.”
Vicki Wilson, Diagnostics Product Manager at DxS, added: “I am very pleased to have joined DxS. This is an exciting time to be at the company, and I look forward to being part of its ongoing success.”
Vicki’s appointment comes on the back of a successful year for DxS, having announced expansion plans and a major global distribution agreement with Roche Molecular Diagnostics. In addition June saw the ASCO conference, which highlighted the importance of detecting patients K-RAS mutation status prior to being treated with some targeted colorectal cancer therapies such as Erbitux and Vectibix.
For further information, please contact:
Sue Charles, Tony Stephenson, John McIntyre College Hill Life Sciences +44 (0)20 7866 7864 Tony.stephenson@collegehill.com
